Pioneering Autoimmune CAR T Application: Kyverna is at the forefront of applying CAR T-cell therapy, a highly effective technology from oncology, to severe autoimmune diseases, potentially establishing a first-mover advantage in this novel therapeutic area.

Potent B-Cell Depletion Mechanism: KYV-101's CD19 CAR T targets and depletes B cells, which are central drivers of many autoimmune conditions, offering a highly specific and potentially more profound and durable therapeutic effect than conventional immunosuppressants.

Positive Early Clinical Data Validation: Initial clinical trial results, particularly from the LUMEN study in lupus nephritis, have demonstrated promising efficacy and safety for KYV-101, providing early proof of concept and de-risking the platform.